• Molecular NameAmsacrine
  • SynonymAcridinyl Anisidide; M-AMSA; MAMSA
  • Weight393.467
  • Drugbank_IDDB00276
  • ACS_NO51264-14-3
  • Show 3D model
  • LogP (experiment)5.273
  • LogP (predicted, AB/LogP v2.0)4.65
  • pkaN/A
  • LogD (pH=7, predicted)1.7
  • Solubility (experiment)<1 mg/mL
  • LogS (predicted, ACD/Labs)(ph=7)-4.68
  • LogSw (predicted, AB/LogsW2.0)0.0
  • Sw (mg/ml) (predicted, ACD/Labs)0.01
  • No.of HBond Donors2
  • No.of HBond Acceptors6
  • No.of Rotatable Bonds5
  • TPSA88.7
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyAn antineoplastic agent.
  • Absorption_valueN/A
  • Absorption (description)Amsacrine is poorly absorbed after oral administration.
  • Caco_2N/A
  • BioavailabilityN/A
  • Protein binding98.0
  • Volume of distribution (VD)1.67 L/kg
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmIt is metabolised in the liver mostly as amasacrine–glutathione metabolites.
  • Half life7 h; 1.5 in plasma
  • ExcretionIt is excreted primarily in the bile by an active transport mechanism. >20% of the drug is recovered unchanged in urine.
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityN/A
  • LD50 (rat)N/A
  • LD50 (mouse)N/A